^
Association details:
Evidence:
Evidence Level:
Sensitive: B - Late Trials
New
Source:
Title:

1265P - Toripalimab plus chemotherapy as neoadjuvant treatment for resectable stage IIB-IIIB NSCLC (RENAISSANCE study): A single-arm, phase II trial

Published date:
10/16/2023
Excerpt:
Pts with resectable stage IIB-IIIB, wildtype EGFR/ALK NSCLC were eligible. All pts received 2-4 cycles of toripalimab (240mg, q3w) plus double platinum-based chemotherapy….Neoadjuvant toripalimab plus chemotherapy resulted in promising MPR rate and manageable toxicity for patients with resectable stage IIB-IIIB NSCLC.
Secondary therapy:
Chemotherapy
Trial ID:
Evidence Level:
Sensitive: B - Late Trials
Title:

Toripalimab Plus Chemotherapy for Patients With Treatment-Naive Advanced Non–Small-Cell Lung Cancer: A Multicenter Randomized Phase III Trial (CHOICE-01)

Published date:
10/07/2022
Excerpt:
Patients (N = 465) with treatment-naive, advanced NSCLC without EGFR/ALK mutations were randomly assigned 2:1 to receive toripalimab 240 mg (n = 309) or placebo (n = 156) once every 3 weeks in combination with chemotherapy...Toripalimab plus chemotherapy significantly improves PFS and OS in patients with treatment-naive advanced NSCLC
Secondary therapy:
Chemotherapy
DOI:
10.1200/JCO.22.00727
Trial ID:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
Title:

Toripalimab in Combination With Platinum-based Chemotherapy for Mutation-negative Stage IV Oligometastatic NSCLC

Excerpt:
...- Proved EGFR, ALK, ROS1 wild-type non-small cell lung cancer....
Trial ID:
Evidence Level:
Sensitive: C3 – Early Trials
Title:

WS08.22 - Neoadjuvant Toripalimab Combination in Patients with Stage IIB-IIIB NSCLC: A Single-arm, Phase 2 Trial (Renaissance Study)

Published date:
07/12/2022
Excerpt:
39 pts underwent resection (median interval between neoadjuvant treatment and surgery: 67 days, IQR: 39-113). 25 pts (25/39, 64.1%) achieved MPR, including 20 pts (20/39, 51.3%) with pCR. R0 resection was achieved in all 39 pts (100%). 29 pts underwent surgery with cN2/N1 at baseline (29/31, 93.5%) achieved nodal downstaging. 49 pts finished the treatment schedule and radiological reassessment, ORR was 85.7% (42/49). Neoadjuvant toripalimab plus platinum-based doublet is a promising, tolerable and effective treatment for pts with stage IIB-IIIB NSCLC.
Secondary therapy:
cisplatin
Trial ID: